Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Geyser Brands Inc. V.GYSR.H

Healthcare Drug Manufacturers - Major Cannabis
Geyser Brands Inc builds health-based hemp CBD consumer product businesses in the Nutraceutical, Cosmetics, Food and Beverage and Pet Sectors. Research and Development investment in Nanofusion, proprietary all-natural nanotechnology, delivers creams, beverages, backed goods and tincture formulations with superior bio-availability and water-solubility.


TSXV:GYSR.H - Post by User

Geyser Brands Inc. > We are all red but revenue is in route
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by ZincMan1on Aug 29, 2019 3:57pm
57 Views
Post# 30080620

RE:RE:RE:We are all red but revenue is in route

RE:RE:RE:We are all red but revenue is in routeOnce again Brownie.. your gums are flapping.. and you have no idea what you're talking about. Go back to your hole!


Revenue The Company achieved its first revenue during F2020-Q1. Revenue was $79,434 arising primarily from the sale of its CBD-dominant cannabis crop by wholly owned subsidiary, 0957102 B.C. Ltd. (dba Apothecary Botanicals). The revenue was a wholesale distribution to another Licensed Producer (“LP”) ultimately for sale to their medical marijuana customers. The crop was comprised of “Orange Bud” and “Master Kush” strains of cannabis and was the second harvest for Geyser.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities